Skip to main content

Day: June 2, 2025

Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance

Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025 (announcement No 2). Please read the full announcement in PDF.Attachment2025_Closing_of_the_Feed_Enzyme_Alliance

Continue reading

Dynacor Group Declares June 2025 Dividend

MONTRÉAL, June 02, 2025 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announced its monthly dividend payment for June 2025 in the amount of C$0.01333 per common share which will be payable on June 18, 2025, to shareholders of record as of the close of business on June 11, 2025. This dividend represents the sixty-third (63rd) dividend and fifty-third (53rd) monthly dividend payment made to shareholders. The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes.The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board. About Dynacor Dynacor Group is an industrial ore processing company...

Continue reading

SAIC Announces First Quarter of Fiscal Year 2026 Results

Revenues of $1.88 billion; approximately 2% revenue growth Net bookings of $2.4 billion; book-to-bill ratio of 1.3 Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues Diluted earnings per share of $1.42; Adjusted diluted earnings per share(1) of $1.92 Cash flows provided by operating activities of $100 million; Free cash flow(1) of $(44) million Management reaffirms fiscal year 2026 guidanceRESTON, Va., June 02, 2025 (GLOBE NEWSWIRE) — Science Applications International Corporation (NASDAQ: SAIC), a premier Fortune 500 technology integrator driving our nation’s digital transformation across the defense, space, civilian, and intelligence markets, today announced results for the first quarter ended May 2, 2025. “Our performance in the first quarter reflects the steady progress we are...

Continue reading

GFG Announces Encouraging Phase 1 Drill Results from Pen Gold Project, Ontario

Gold and base metals mineralization intersected at multiple targets; exploration budget increased to support aggressive H2 program KEY HIGHLIGHTS:Chabot Target: 3.90 grams of gold per tonne (“g/t Au”) over 3.5 metres (“m”), including 9.62 g/t Au over 1 m near surface (PEN-25-100); second zone returned 2.6 g/t Au over 1.3 m with over 1% zinc (1). Alpha Target (Muskego North Shear Zone): 1.00 g/t Au over 1.0 m (MSK-25-004), confirming the down-dip extension of a 2022 bedrock sample that graded 5.18 g/t Au. Foxtrot, Bravo, Charlie, and Delta Targets: Multiple zones of stratabound and remobilized sulphide mineralization with elevated gold, copper, and zinc values in structurally and lithologically favorable settings. Pending results from an additional 5 drill holes at the Aljo Gold Target (“Aljo”) to be released as they become available....

Continue reading

Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company for $4.65 Million as Part of Company Streamlining

Proceeds to Support Company’s Strategic Focus on Data Center Business LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the sale of its minority equity interest in a privately held pharmaceutical company for gross proceeds of $4.65 million in cash.   Hyperscale Data purchased the equity position for $1.5 million in several closings between three and four years ago. This transaction is consistent with the Company’s ongoing strategy to exit non-core investments and concentrate capital and resources on its primary asset—a 617,000 square foot data center located in Michigan, which is being developed to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”) applications. “As...

Continue reading

Piedmont REIT Signs over 500,000 SF of Leases Second Quarter-to-Date and Raises Full Year Leasing Guidance from 1.4 – 1.6 million SF to 1.8 – 2.0 million SF

YTD Leasing of over 850,000 SF Atlanta, June 02, 2025 (GLOBE NEWSWIRE) — Piedmont Office Realty Trust, Inc. (“Piedmont” or “the Company”) (NYSE:PDM), an owner of Class A office properties located primarily in the Sunbelt, announced today, that the Company is participating in this week’s Nareit REITWeek Investor Conference in New York City. The Company has completed over 500,000 square feet of leasing thus far in the second quarter, with 350,000 square feet related to new tenants. Approximately 70% of the new tenant leases are for currently vacant space and year-to-date leasing volume now totals over 850,000 square feet.   Of note, the Company signed two new, large transactions in excess of 10 years – 93,000 square feet with a global professional services firm specializing in risk, strategy and people at Three Galleria...

Continue reading

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launchMORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. Food and Drug Administration (FDA) approval of YUTREPIA on May 23,...

Continue reading

First Atlantic Nickel to Attend Benchmark Mineral Intelligence’s GIGA USA 2025 Conference, Highlighting Atlantic Nickel Project’s Smelter-Free Processing for North America’s Critical Minerals Supply Chain

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) — First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) is pleased to announce its participation at the Benchmark Mineral Intelligence GIGA USA 2025 conference, taking place June 3-4, 2025, in Washington, DC. The Company will participate in strategic meetings during this critical mineral conference to demonstrate how its Atlantic Nickel Project addresses the growing need for nickel mining that can be completely processed in North America. The Atlantic Nickel Project contains nickel in the form of awaruite, a naturally occurring, sulfur-free, highly magnetic mineral with approximately 75% nickel content. These unique properties enable direct processing through magnetic separation and flotation, eliminating reliance on foreign...

Continue reading

BranchOut Food Inc. Announces Plan to Eliminate Current Liability Notes Payable with $1 Million Warrant Exercise and Extension of Key Financing Agreements

Kaufman Kapital exercises warrant and extends key debt maturities, providing $1 million in support of BranchOut’s financial strategy BEND, Ore., June 02, 2025 (GLOBE NEWSWIRE) — BranchOut Food Inc. (NASDAQ: BOF), a leading food technology company specializing in its patented GentleDry™ dehydrated snacks and ingredients, announces the execution of a strategic agreement with Kaufman Kapital LLC, resulting in a $1 million cash infusion through the early exercise of existing warrants. The agreement also includes amendments to existing financing terms that strengthen BranchOut’s balance sheet, allow for debt repayment and extend key debt maturities. Under the terms of the agreement, Kaufman Kapital will exercise in full an existing warrant to purchase 1,000,000 shares of BranchOut’s common stock, providing the Company with $1,000,000...

Continue reading

Xilio Therapeutics Announces Proposed Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is commencing an underwritten public offering of pre-funded warrants to purchase shares of common stock accompanied by Series A warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants), Series B warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants) and Series C warrants to purchase shares of common stock (or, in certain circumstances, pre-funded warrants). All of the securities to be sold in the proposed offering will be offered by Xilio. The proposed offering is subject to market and other conditions,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.